"Pharmaceutical headlines" 20,000 private hospitals Why ophthalmology into the most beautiful baby?

(2020/09/08) Roche PD-L1 inhibitors in China won 4 clinical approvals for non-small cell lung cancer, etc.; (Click on the title, can obtain the original text) "Pharmaceutical 1st time" Roche PD-L1 inhibitor in China to win 4 clinical approvals for non-small cell lung cancer and so on today, according to the latest publicity on the CDE website, Roche's PD-L1 inhibitor Tecentriq (atezolizumab, Atili pearl monoanti) was approved again 4 clinical.
It is understood that this approved development of adaptive disorders are: atili pearl monoanti-anti-combination tiragolumab, used in patients with stage III non-small cell lung cancer with no progression after platinum-containing programme chemotherapy; Treatment after hepatic arterial chemotherapy embolism (TACE); atili-pearl monoantigen combination low-dose radiotherapy, cisplatin/carptonin, etoposide, treatment of broad-stage small cell lung cancer; and atholi-pearl monoantigen and beva-pearl monoantigen combination carptin or cisplatin and etoposide were used in untreated patients with extensive stage small cell lung cancer.
: I believe there is still a lot of room for growth in the future.
20,000 private hospitals, why is ophthalmology the most beautiful? The outbreak has not stopped its upward momentum, but public hospitals are on the fringes and overall income levels and profit contributions are relatively low.
Ophthalmology is highly replicable, funding is well positioned, monolithic clinics are mostly invested in less than 30 million, free from capital expansion pressures of more than hundreds of millions of dollars (e.g. psychiatric, obstetrics and gynecology, etc.) and uninhibited by low costs that cause doctors to practise on their own (e.g. dentistry).
: more competitors, ordinary people can enjoy more cost-effective services.
"E drug manager" national team rapid layout MNC heavy gold bet: standing in the air mouth of the medical big data will go to September 7, zero-yuan technology announced to obtain 700 million yuan D-plus round of financing, began to fully accelerate the serious illness "medical-drug-risk" commercial closed-loop landing.
is believed to be the first unicorn company in the field of medical big data and artificial intelligence, having previously received multiple rounds of financing.
: Multinational pharmaceutical companies aim at ecological construction.
260 million! On September 7th, Haisco Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of Sichuan Haisco Pharmaceutical Co., Ltd., signed the Patent Implementation License Agreement and related agreement with Chengdu Haitron Pharmaceutical Co., Ltd. ("Haitron Pharmaceuticals") on September 4, 2020.
: How will Hesco adjust its future research and development strategy? "Medical Valley" about 70% of the original research of Soraphini domestic first imitation price announced recently, according to the Inner Mongolia Autonomous Region pharmaceutical centralized procurement network issued a notice that Jiangxi Shanxiang Pharmaceutical Toluene Sulfini tablets (specs: 0.2g x 60 tablets) to give supplementary hanging network, procurement price of 3990.00 yuan / box, September 5, 2020 officially implemented.
: Competition will intensify.
New Horizons' CD47, which attracted AbbVie to bet on The Wonderland, was on September 4th. NASDQ and AbbVie have jointly announced an extensive global strategic partnership for the development and commercialization of Tianbi Bio's innovative CD47 single-resistant lemzoprlimab (TJC4), which will receive a total of $1.94 billion in installment milestone payments and a two-digit tiered royalty for future global sales.
this cooperation has become another milestone in China's innovative pharmaceutical industry.
: Another rich new continent in the field of tumor immunity.